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Background: Over the last decade, evidence has accumulated that vascular risk factors increase 
the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on 
lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) 
evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia 
or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, 
  hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, 
with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins 
(2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention 
of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering 
homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of 
antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on 
cognitive decline and dementia in later life is scarce and mostly based on secondary outcome 
parameters. Several important sources of bias such as differential dropout may importantly 
affect interpretation of trial results.
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Apart from a dramatic impact on the personal life of patients and their caregivers, 
dementia places a high burden on social and economic resources. With an ageing 
population, the prevalence of dementia will continue to rise in the coming decades. 
Since effective treatments are lacking, prevention of dementia deserves high priority. 
Alzheimer disease (AD) and vascular dementia (VaD) are the most prevalent forms 
of dementia, together accounting for up to 80% of all cases of dementia.1
The strict division between AD and VaD has faded with advancing research in 
neuropathology, neuroradiology, and epidemiology. In recent years, the vascular 
component of AD has become increasingly recognized.2 Several cohort studies have 
shown that in most dementia patients, irrespective of their clinical diagnosis, mixed 
pathology is found at autopsy, including mostly Alzheimer changes (amyloid-β plaques 
and intracellular tangles) and cerebrovascular lesions (both infarcts and white matter 
lesions (WML)).3–5 Imaging studies have shown that WML and silent cerebral infarcts 
increase the risk of future dementia and that cerebrovascular lesions are common in 
AD, where they contribute to dementia severity.6,7Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Presently, compelling evidence from numerous prospec-
tive cohort studies of the relationship between vascular risk 
factors and cognitive deficits has been found. Hypertension, 
dyslipidemia, hyperhomocysteinemia, obesity, and diabetes 
mellitus (DM) at midlife have all been associated with an 
increased risk of cognitive decline and dementia in later 
life.8–12 In several observational studies, the use of antihy-
pertensive drugs and statins, as well as the intake of folate, 
vitamin B6, and vitamin B12 have been associated with a 
decreased risk of dementia.13–16
Results from a recent randomized controlled trial (RCT) 
show that an intervention aimed at improving cardiovascular 
risk profile can slow down the progression of WML in early 
AD, but has no effect on cognition, behavior, or activities of 
daily living.17 Whether treatment of vascular risk factors in 
cognitively intact elderly can postpone or prevent cognitive 
decline and dementia is subject to debate.
In this systematic review we give an overview of RCTs 
in which the effect of established medical treatments of 
vascular risk factors on cognitive decline and dementia is 
studied. Lifestyle alterations such as exercise programs and 
diet are not in the scope of this review. Potential sources 
of bias in this specific field are discussed, as well as future 
research.
Objective
To systematically review all RCTs in which the effect of 
medical treatment aimed at vascular risk factors, ie, hyper-
tension, dyslipidemia, hyperhomocysteinemia, obesity, and 
DM type II on the incidence of dementia or cognitive decline, 
were investigated.
Methods
Literature review
A systematic literature review was carried out to identify all 
available RCTs in which the effect of treatment of established 
vascular risk factors on the incidence of all cause dementia or 
cognitive decline was studied. We searched for RCTs from 
1990 onwards because the relationship between vascular 
risk factors and all forms of dementia was not widely recog-
nized before this time. The search was restricted to articles 
in English and we were assisted by a clinical librarian with 
experience in performing systematic reviews. Only RCTs 
were included in this review, to minimize the influence of all 
forms of bias, and particularly selection bias. To be able to 
find any effect on dementia or long-term cognitive decline, 
studies targeting elderly people (mean age at baseline at 
least 60 years) and with a follow-up of at least 1 year, were 
considered eligible.
All studies in which results on cognitive decline or 
dementia were reported were included in this review, leav-
ing precise definition of cognitive decline to the discretion 
of the original investigators. The sensitivity and clinical 
relevance of different testing methods are subject to debate 
and are addressed later in this review.
The following (Mesh) search terms were used: 
  (“randomized controlled trial” or “controlled clinical 
trial” or “randomized” or “randomly” or “trial”) in com-
bination with (“dementia” or “mild cognitive impairment” 
or “Alzheimer” or “cognitive decline”) and (“older” or 
“elder*” or “aged” or “later life”) and the following search 
terms: a) “hypertension” or “antihypertens*” or “blood pres-
sure” b) “cholesterol” or “dyslipidemia” or “hypercholester-
olemia” or “lipid lowering” c) “homocysteine” d)“diabetes 
mellitus” or “glucose control” or “diabetes” or “diabetic” 
or “hypoglycemic” and e) “adiposity” or “obesit*”.
MEDLINE (PubMed) was searched on November 30, 
2009. First, articles were scanned on titles and abstracts inde-
pendently by two reviewers (SL, ER). Articles were retained 
if they met the following inclusion criteria: 1) original 
randomized controlled intervention trial; 2) drug treatment 
intervention targeted at lowering blood pressure, improving 
lipid profile, lowering homocysteine, optimizing treatment 
of diabetes mellitus type II, or treating overweight; and 3) 
assessing cognitive decline or incident all-cause dementia as 
primary or secondary outcome parameters in a population 
with a mean age of at least 60 years and a follow-up time 
of at least 1 year. EMBASE and the Cochrane Central reg-
ister of Controlled trials (clinical trials) were searched with 
the same keywords. In addition, the Cochrane Database of 
Systematic Reviews was explored using the search terms 
(dementia or “mild cognitive impairment” or Alzheimer or 
“cognitive decline”) to identify existing systematic reviews 
on this topic. Finally, reference lists of all articles identified 
were searched.
Data collection
Articles that met inclusion criteria were analyzed by two 
reviewers (SL, ER). Data on type and number of participants, 
intervention, (the effect on) primary outcomes, outcome 
measures on cognitive decline or dementia, duration of 
follow-up, completeness of follow-up, and conclusions drawn 
by authors were collected. The main limitations of each study 
were identified as well as main strengths.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Results
The MEDLINE search yielded 1292 articles, of which 
87 were selected by screening titles and abstracts. The 
EMBASE search (1362 articles) yielded one additional 
study that was not found in the initial search in PubMed. In 
the Cochrane search (880 articles) no additional RCTs were 
found. Finally, 16 original studies (43 papers) were included 
in this review; six on hypertension, two on dyslipidemia, 
none on obesity, one on diabetes mellitus type II, six on 
lowering homocysteine, and one study with a multifactorial 
intervention. Three additional studies on cardiovascular and 
diabetes management are ongoing and will be described in 
this review, as well as the main characteristics of excluded 
studies. The Cochrane search for systematic reviews revealed 
six systematic reviews for separate risk factors: one on hyper-
tension, one on statins, one on diabetes mellitus, and three 
on B vitamins. These will be discussed below.
excluded studies
After selection based on titles and abstracts, studies were 
excluded subsequently for the following reasons: mean   follow 
up shorter than 1 year (n = 35), mean age of   participants ,60 
years (n = 3), cognitive decline or dementia was no primary 
or secondary outcome (n = 2), and participants already 
  suffering from AD (n = 4). Many studies on antihypertensive 
treatment conducted between 1990 and 1995 compared the 
effect of two antihypertensive agents (eg, a beta-blocker and 
an ACE-inhibitor) on cognitive function to rule out a negative 
short term effect of medication on cognition (for examples 
see Fogari et al18 or Goldstein et al).19 The follow-up time 
was short (from several weeks to a maximum of 6 months), 
rendering these studies prone to a type II error for the evalua-
tion of long-term effects on cognition. In general, no adverse 
effects of antihypertensive treatment on short-term cognition 
were reported.
Four studies on diabetes management were excluded 
due to their having relatively young populations (mean age 
52 years) with a short follow up (6–24 weeks), reporting no 
or only small positive effects of glycemic control on some 
domains of short-term cognitive function or quality of life.20–23 
Excluded studies in which treatment was aimed at lowering 
homocysteine levels were often restricted to 6 months.24,25
Hypertension
Six studies evaluating the relationship between antihyperten-
sive treatment and cognitive decline/dementia were identified 
(see Table 1 for details).
The number of participants in studies ranged from 2418 
to 6105. In all studies, cognitive decline and dementia were 
measured as secondary outcome parameters. Age at inclusion 
varied from $60/65 years (SHEP,26,27 MRC,28 Syst-Eur,29,30 
PROGRESS31), to $70 years (SCOPE32,33), and even to 
$80 years (HYVET).34 Generally, participants with a systolic 
blood pressure of $160 mmHg (both treated and untreated 
in SHEP/SCOPE/HYVET) and without prior stroke were 
eligible, except for PROGRESS in which only participants 
with a stroke or transient ischemic attack (TIA) in the previ-
ous 5 years were included, regardless of blood pressure. An 
upper limit of 179 mmHg for systolic blood pressure was 
an inclusion criterion in the SCOPE trial, in contrast to the 
other studies.
All included studies on hypertension are placebo-
  controlled trials. In five trials a diuretic was part of the study 
medication, in combination with a beta-blocker (n = 2) or 
ACE-inhibitor (n = 3). In SCOPE an angiotensin II type 1 
(AT1) receptor blocker was the studied drug, whereas Syst-
Eur was the only trial in which a calcium channel blocker 
was studied (combined with an ACE-inhibitor and/or diuretic 
if necessary).
Many patients received additional (open label) antihy-
pertensive medication in both groups to achieve acceptable 
blood pressure values. For example, in Syst-Eur, half of the 
patients in the placebo group remained on their original 
study medication and in the MRC trial this was only 38%. In 
SCOPE, 84% of participants in the placebo group received 
antihypertensive medication.
To assess cognitive function, the Mini-Mental State 
Examination (MMSE), a widely used screening instrument 
for cognitive impairment, was used in most studies (Syst-Eur, 
SCOPE, PROGRESS, and HYVET). In the SHEP study, cog-
nitive screening was performed by the short-comprehensive 
assessment and referral evaluation (short-CARE) question-
naire. The PALT (paired associate learning test) and the TMT 
(trail making test) were used in the MRC trial to measure 
cognition. In one center of the SCOPE trial (n = 257), an 
additional extensive assessment battery was used to assess 
cognition.33
Follow-up of the included trials ranged from 2.2 years 
(HYVET) to 5 years (SHEP). In a study by Di Bari et al the 
risk of  “differential dropout” is highlighted with regard to 
the SHEP trial.27 This selective dropout of patients is espe-
cially plausible in the case of cognitive decline or dementia, 
in which progression of symptoms could lead to unwilling-
ness to participate further in the study. In addition, loss to Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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follow-up is likely to occur more frequently when cognitive 
decline or dementia is present, because of high rates of insti-
tutionalization among these patients in comparison to healthy 
elderly participants. Under the assumption that hypertension 
is a risk factor for dementia, participants in the placebo group 
or participants with a high risk of cardiovascular events or 
a history of cardiovascular disease would be more likely 
to develop cognitive decline or dementia and as a conse-
quence would also be more likely to end study participation. 
In the SHEP study, occurrence of cardiovascular events and 
assignment to placebo were both independently predictive 
for missed assessments.27 This potential selective dropout 
of patients is probably not specific to the SHEP study. In 
the MRC trial the dropout rate was high (the exact number 
of patients still included at follow-up was not reported) and 
participants that were lost to follow-up had lower cognitive 
scores at baseline. In the Syst-Eur substudy on cognition, 
76% of participants were willing to participate and, of these, 
22% were not evaluated because of early trial termination of 
their participation (less than 1 year).
The primary outcome parameters in all studies were 
stroke only or stroke in combination with coronary 
  events/myocardial infarction and (cardiovascular) death. 
In all studies, the incidence of fatal and nonfatal stroke was 
significantly reduced. The relative risk reduction for stroke 
varied from 24% (SCOPE) to 42% (Syst-Eur). HYVET was 
the first RCT to report the effects of antihypertensive treat-
ment in participants aged 80 years and older and showed 
a significant decrease of stroke after an average follow-up 
of 2.2 years, which led to early termination of this study. 
Participants were mostly recruited in Eastern Europe and 
China (95%) where the risk of stroke is higher than in 
Western Europe.35 In 5 of 6 studies, no significant effect on 
the incidence of dementia was found. The Syst-Eur trial, of 
which the first results were published in 1998, was the only 
RCT that showed a convincing decrease on incidence of 
dementia by 50% after two years and 55% after a mean of 
3.9 years of follow-up.
In the SCOPE trial no differences in incident dementia 
or MMSE score were found. In a subgroup analysis that was 
performed later and published in 2008, a significant positive 
effect on some cognitive domains (attention and episodic 
memory) was reported through more sensitive   testing   methods 
than the MMSE. The clinical relevance of these results is 
Table 1 Hypertension
Authors (study 
name), year of 
publication
Population 
characteristics
Intervention  
(number of 
participants)
Primary end 
points (% RRR  
for stroke)
Mean  
follow-up
Effect on cognitive 
function (test)
SHeP, SHeP 
study group,26,27 
1991
isolated systolic HTN 
(160–219 mmHg),  
age $60 y
chlorthalidone ± atenolol 
or reserpine versus 
placebo (n = 2365/2371)
fatal/nonfatal stroke 
(36%)
5.0 y no significant difference in 
incidence of CD 
(shortCARe)
MRC trial,  
Prince et al28 
1996
not on anti- 
hypertensive 
medication, age  
65–74 y
hydrochlorothiazide/ 
amiloride or atenolol 
versus placebo 
(n = 633/640/1311)
stroke/coronary 
events/mortality 
(31%)
4.5 y no effect on cognitive 
performance 
(PALT, TMT A)
Syst-eur,  
Forette et al29,30  
1998, 2002
systolic HTN (160– 
219 mmHg), 
age $60 y
nitrendipine ± enalapril 
± hydrochlorothiazide 
versus placebo 
(n = 1238/1180)
stroke (42%) 3.9 y 55% decrease in incidence 
of dementia (MMSe)
SCOPe, Lithell 
et al32,33 
2003/2008
treated or untreated 
systolic HTN (160– 
179 mmHg),  
age 70–89 y
candesartan versus 
placebo (n = 2477/2460)
stroke, Mi, 
cardiovascular 
mortality (24%)
3.7 y no decrease in incidence of 
dementia 
slightly less cognitive decline 
in those with MMSe  
24–28/stroke (MMSe)
PROGReSS 
Tzourio et al31 
2003
previous stroke or 
TiA, mean age 64 y
perindopril versus 
placebo. indapamide 
added in both groups 
when necessary 
(n = 3051/3054)
recurrent stroke 
(28%)
3.9 y decrease in cognitive 
decline (3 or more on 
MMSE), non-significant 
decrease in 
dementia (MMSe)
HYVeTCog,  
Peters et al34  
2008
systolic HTN (160– 
200 mmHg),  
age $80 y
indapamide ± 
perindopril versus 
placebo (n = 1687/1649)
stroke (30%) 2.2 y no decrease in incidence of 
dementia (MMSe)
Abbreviations:  RRR,  relative  risk  reduction;  y,  years;  HTN,  hypertension;  CD,  cognitive  decline;  PALT,  paired-associate  learning  test;  TMT,  trail  making  test; 
MMSe, Mini-Mental State examination; Mi, myocardial infarction; TiA, transient ischemic attack.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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questioned by the authors. In the PROGRESS trial, cognitive 
decline (defined by a decrease in MMSE score of 3 or more 
points) was significantly lower in the treatment group (9.1% 
versus 11.0%, P = 0.01) next to a nonsignificant decrease of 
incident dementia (6.3% versus 7.1%, P = 0.2).
The results of the most recent HYVET-Cog study on 
indapamide with or without perindopril show a nonsignificant 
effect of antihypertensive treatment with a hazard ratio for 
incident dementia of 0.86 (95% CI 0.67–1.09). When these 
results were combined with the results of SHEP, Syst-Eur, 
and PROGRESS in a meta-analysis, the hazard ratio was 
0.87 (95% CI 0.76–1.00).34
One Cochrane systematic review is available (2009), only 
for patients without prior cerebrovascular disease, in which 
also the (single blind) MRC trial was excluded.36 The authors 
conclude that the available evidence for prevention of cogni-
tive impairment or dementia by blood pressure lowering in late 
life is not conclusive. Two potential sources of substantial bias 
were recognized: the large number of patients lost to follow-up 
and active treatment of blood pressure in placebo groups that 
may have led to underestimation of a treatment effect.
Dyslipidemia
Two randomized clinical trials that met our inclusion 
  criteria evaluated the effect of statin use on cognition 
(Table 2). The Heart Protection Study (HPS) compared the 
use of simvastatin 40 mg to placebo in 20,536 participants 
aged 40–80 (5806 . 70 y),37 and the PROSPER study 
compared pravastatin 40 mg to placebo in 5804 participants 
aged 70–82 (mean 75.3).38,39 Dyslipidemia was not required 
for inclusion in either trial. Lipid levels at baseline were 
largely comparable between the two studies, with total 
cholesterol (in mmol/L) of 5.9 (HPS) and 5.7 (PROSPER), 
LDL 3.4 (HPS) and 3.8 (PROSPER), and triglycerides 
2.1 (HPS) and 1.5 (PROSPER). Levels of LDL were suc-
cessfully reduced in HPS and PROSPER (-1.4 and -1.3 
respectively).
Participants were included in HPS if they were   considered 
to be at a substantial 5 year risk of death from coronary 
heart disease based on medical history (coronary disease, 
noncoronary occlusive disease, diabetes, or hypertension). 
Participants were included in PROSPER if they had preex-
isting vascular disease (coronary, cerebral, or peripheral) or 
were considered to be at increased risk for this, because of 
smoking, diabetes, or hypertension. Non-study statin treat-
ment occurred in the placebo group in 10% in PROSPER 
and this was on average 17% in HPS (ranging from 4% in 
the first year to 32% at the end of the fifth year). HPS had 
an average follow-up of 5 years and PROSPER of 3.5 years. 
The primary outcome parameters in HPS were mortality and 
fatal and nonfatal vascular events, and in PROSPER the 
primary outcome parameter was a composite endpoint of cor-
onary death, nonfatal myocardial infarction, and fatal or non-
fatal stroke. Both trials used cognitive function as a secondary 
outcome parameter. In the HPS no cognitive assessment was 
made at baseline, and at follow-up the Telephone Interview 
for Cognitive Status (TICS) was used. In the PROSPER, four 
cognitive outcome parameters were used: MMSE, two tests 
for executive function (Stroop color-word test and the letter 
digit coding test), and one memory test (15 Picture Learning 
test, PLT). No effect on any of the used cognitive outcome 
parameters was found in either HPS or PROSPER. The HPS 
study reported 23.7% (simvastatin) versus 24.2% (placebo) 
of the participants as having any cognitive impairment at 
follow-up. The PROSPER study reported a decline in all 
measured cognitive domains which was comparable in the 
two groups, as expected with   advancing age in this group. 
Although the methods used to assess cognitive decline in 
both studies, especially the HPS-study, are limited, it seems 
unlikely that different ways of assessing cognitive decline 
would have yielded different results.
Since the publication of a Cochrane review on this 
subject,40 no new trials have been published, except for a 
more detailed description of the cognitive outcomes of the 
Table 2 Dyslipidemia
Authors, year 
of publication
Population 
characteristics 
Intervention (number  
of participants)
Primary end-points 
(outcome)
Follow-up  Effect on cognitive 
function (test)
HPS, HPS study 
group,37 2002 
occlusive arterial 
disease or DM, age 
40–80 y
simvastatin versus 
placebo 
(n = 10269/10267)
all cause mortality/ 
coronary death 
(HR 0.87, p = 0.0003)
5 y no effect on cognition (TiCS)
PROSPeR, 
Shepherd 
et al38,39 2002
history of VAD or 
risk factors, age 
70–82 y
pravastatin versus 
placebo (n = 2891/2913)
coronary death, 
nonfatal Mi, stroke 
(HR 0.85, p = 0.014)
3.2 y no effect on cognitive function 
or disability (MMSe, NP test 
battery)
Abbreviations: DM, diabetes mellitus; y, years; HR, hazard ratio; TiCS, telephone interview for cognitive status; VAD, vascular disease;  MMSe, mini mental state examination; 
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PROSPER study.41 We can conclude that there is no evidence 
that the use of statins in elderly participants has a favorable 
effect on cognitive decline.
Hyperhomocysteinemia
Six studies on lowering homocysteine were identified. 
Overall, plasma homocysteine lowering was achieved by 
prescribing a combination of folic acid and other high dose 
B vitamins (vitamin B6, vitamin B12).
The total number of participants varied from 185 to 2009 
per study. Patients were mostly selected on elevated serum 
total homocysteine levels ($13 or $15 mmol/L), apart from 
the studies by Stott et al42 and Kang et al43 in which homo-
cysteine levels were not specificed and only patients with 
high risk of cardiovascular disease (ischemic heart disease, 
TIA/stroke, peripheral arterial disease) were included. In the 
substudy by Viswanathan and colleagues,44 150 participants 
from each treatment arm of the original VISP study with 
the highest plasma homocysteine levels and who did not 
have a stroke during follow-up were post-hoc included for 
analysis of cognitive function. The study by Brady et al45 was 
aimed at a specific patient group with high levels of plasma 
homocysteine in combination with chronic or end-stage renal 
disease, of whom 36% was on hemodialysis. The studies 
by Brady et al and Viswanathan et al included very young 
patients (.21 and .35 years respectively), but average age 
of inclusion was similar to the other studies with 67 years.
In most studies, a combination of folic acid, vitamin B6, 
and vitamin B12 was used to lower homocysteine levels,   versus 
placebo or a low dose B vitamins (Viswanathan et al). In 
the study by Stott et al folic acid was compared with the 
addition of vitamin B6, vitamin B12, or riboflavin versus 
placebo in 7 different groups (n = 23/group). Durga et al46 
assessed oral folic acid without other B vitamins versus 
placebo in patients with high homocysteine and low 
vitamin B12 levels.
Incident dementia was never an outcome in the included 
studies. Cognitive decline was the primary outcome in the 
studies by Durga et al46 and McMahon et al47 in which more 
extensive tests than the MMSE or TICS (a telephone   version 
of the MMSE) only were used. Several combinations of 
neuropsychological tests were used in the different studies 
to measure cognition (see Table 3 for details).
Dropout rates varied from 0% to 26% in these studies. 
In the substudy from Viswanathan, there was no loss to fol-
low up, while the original study suffered from high dropout 
(17%), suggesting selection bias. The substudy on cognition 
started when the original study was already ongoing. This was 
also the case for the studies by Kang et al and Brady et al in 
which the studies on cognition started 1.2 and 4 years after 
the start of the original study, respectively.
The studies by McMahon et al and Durga et al were 
designed specifically to measure cognitive function. In the 
other trials, primary outcome parameters were vascular events 
or mortality except for the study by Stott et al in which the 
primary outcome parameter was plasma homocysteine level. 
In this study, a large effect on plasma homocysteine in the 
group treated with folic acid and vitamin B12 was achieved. 
In the study by McMahon et al plasma homocysteine con-
centration was decreased significantly but with no difference 
between the two groups.
In 5 of 6 studies, no effect was found of the lowering of 
plasma homocysteine levels on cognitive function. McMahon 
et al even found that patients in the intervention group scored 
significantly lower on one of the many subscales (trail mak-
ing test B), which led to a lower combined cognitive score 
in the vitamin group (P = 0.05) than the placebo group.48 
This is considered a chance finding by the authors. Only 
Durga et al found improvement in 3 of 5 cognitive domains 
(memory, processing speed, and sensorimotor speed). The 
authors themselves suggest as possible explanations: the long 
follow up (3 years), low dropout (1%), and sensitive mea-
surement of cognitive screening next to adequate selection 
of high risk patients (both high plasma homocysteine and 
low vitamin B12 status).
Three Cochrane systematic reviews were identified in our 
search. One review on the short-term effect of vitamin B6 
found no benefit on cognition. In one review on vitamin B12 
it was concluded that there was insufficient evidence for an 
effect on cognition. The review on folic acid with or without 
vitamin B12 and including the trial by Durga et al yielded 
inconsistent results and it was concluded that further research 
is required.49
Diabetes mellitus type ii and obesity
Completed studies on the effect of medical treatment on 
reducing overweight on cognitive decline or dementia were 
not found. The ADVANCE study by Patel et al was the only 
completed study on type II diabetes mellitus management 
that was identified.50 Participants were suffering from type II 
diabetes and had a history of macro- or microvascular disease 
or at least one other cardiovascular risk factor. In total, 5571 
participants with a minimum age of 55 years and a mean age 
of 66 years were randomized to intensive glucose control and 
5569 to standard glucose control. The intervention consisted 
of the prescription of gliclazide modified release 30–120 mg, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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with the addition of metformin, thiazolidinediones, acarbose, 
or insulin if necessary to reach the target glycated hemo-
globin value of 6.5% or less. After a mean of five years of 
follow-up, glycated hemoglobin was 6.5% in the interven-
tion group versus 7.3% in the control group. There was a 
significant treatment effect on major microvascular events, 
mainly because of a reduction of incident nephropathy in 
the intervention group. There were no effects on all cause 
mortality or major cardiovascular events such as stroke or 
myocardial infarction, or on cognitive decline as measured 
with the MMSE or dementia, with a nonsignificant increased 
number of cases of incident dementia in the intervention 
group (61 versus 48 cases).
The ongoing Accord-Mind trial is designed to assess 
the effects of long term glycemic control on cognition.51 
Up to now, only baseline characteristics have been pub-
lished (n = 2977). Participants aged 55 years or older are 
  randomized to standard care or intensive glycemic control 
(target HbA1c , 6.0%) combined with either intensive 
treatment of dyslipidemia or systolic blood pressure (target 
blood pressure ,120 mmHg). After 40 months, the effect 
on cognitive outcome will be assessed using an extensive 
test battery including the MMSE, the Rey Auditory Verbal 
Learning Test (RAVLT), and the Stroop test. Evans et al 
found no placebo-controlled RCTs in their Cochrane review 
on treatment of type II DM and the development of cognitive 
impairment and dementia.52
Multicomponent interventions
One study with a multicomponent intervention to prevent 
recurrent cardiovascular events and cognitive decline 
in patients aged 75 years and older was identified: the 
DEBATE study.53 Of 400 included patients with vascular 
disease (mean age 80 years, all with a history of   myocardial 
Table 3 Hyperhomocysteinemia
Authors, year of  
publication
Population 
characteristics
Intervention 
(number of 
participants)
Primary end- 
points (outcome)
Follow-  
up
Effect on cognitive  
function (test)
Stott et al42 2005 ischemic  
vascular disease,  
age $65 y
oral vit B6, B12,  
folic acid (7  
groups versus  
placebo, n = 185,  
23/group)
plasma  
homocysteine  
(tHcy: 33%  
decrease)
1 y no effect on cognitive function  
(letter digit coding test, TiCS)
McMahon et al47  
2006 
raised tHcy,  
($13 mmol/L),  
age .65 y
oral vit B6, B12,  
folic acid versus  
placebo  
(n = 138/138)
plasma  
homocysteine,  
cognition (no effect  
on tHcy)
2 y no effect on cognition (extensive test  
battery: MMSe, RAVLT, wMS, CwF  
TMT)
Durga et al46 2007  
(substudy FACiT)
tHcy $13 and  
,26 mmol/L. Vit  
B12 , 200 pmol/L,  
age 50–70 y 
(mean: 60 y)
oral folic acid or  
placebo  
(406/413)
cognitive function  
(tHcy 26%  
decrease)
3 y improvements in 3/5 domains (memory,   
processing and sensorimotor speed)  
(word learning, concept shifting, stroop  
test, verbal fluency and letter-digit  
substitution test)
Kang et al43 2008 women with  
CVD or .2  
cardiovascular  
risk factors,  
age .65 y
oral vit B6, B12,  
folic acid versus  
placebo  
(n = 1002/1007)
sec. prevention of  
cardiovascular  
disease (no effect)
5.4 y no effect on cognition (5 telephone 
tests: TiCS, word learning, immediate 
and delayed recall, naming animals)
Brady et al45 2009  
(substudy VA HOST)
chronic kidney  
disease/end- 
stage renal  
disease, tHcy $  
15 mmol/L, age  
$21 y (mean 67 y)
high dose B  
vitamins versus  
placebo  
(320/339)
mortality, vascular  
outcomes (no effect,  
tHcy decrease: 26.7%)
1 y no effect on cognition  
(TiCS, neuropsychological test battery:  
backward/forward digit span, animal  
naming). 
Viswanathan et al44  
2009 (substudy ViSP)
ischemic stroke,  
tHcy $ 15  mmol/L, 
age $35 y  
(mean 67 y) 
high dose  
pyridoxine/vit  
B12/folic acid  
versus low dose  
(n = 157/143)
stroke, Mi, death.  
(no effect)
2 y no effect on cognition. (MMSe)
Abbreviations: Vit, vitamin; tHcy, serum total homocysteine; FU, follow-up; y, years; TiCS, telephone interview for cognitive status; MMSe, Mini-Mental State examination; 
RAVLT, Rey Auditory Verbal Learning Test, WMS, Wechsler Memory Scales; CWF, category word fluency test;  TMT, trail making test; CVD, cardiovascular disease; MI, 
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infarction/coronary artery disease, previous stroke or 
  transient ischemic attack or peripheral artery disease), 
199 were randomized to the intervention group in which 
pharmacological and nonpharmacological treatments were 
optimized by a geriatrician according to current guidelines. 
The 201 participants in the control group received care as 
usual (including secondary prevention programs). The mean 
follow-up was 3.4 years and significant reductions of blood 
pressure and low-density lipoprotein levels were achieved. 
This study was underpowered due to the occurrence of 
fewer events than expected. Intensified vascular care was 
  considered feasible and safe, but no clinical benefits on 
  cardiovascular or cognitive outcome could be identified.
Discussion
Over the past 20 years, several RCTs have focused the effect 
of medical treatment aimed at cardiovascular risk factors 
on cognitive decline and some on incident dementia. Most 
trials discussed in this review had large sample sizes and a 
considerable follow-up time. They were designed to evalu-
ate a treatment effect on mortality and a range of vascular 
outcomes (including stroke, myocardial infarction, and 
peripheral arterial disease) and included cognitive decline 
or incident dementia as a secondary outcome parameter. The 
data on treatment of hypertension, albeit far from conclusive, 
are encouraging. There is a single positive trial (Syst-Eur) 
and a meta-analysis (Hyvet-Cog) that suggest a protective 
effect of hypertension treatment. Since different antihyper-
tensive regimens were used in studies, a specific class-effect 
on cognition of one or more antihypertensive drugs cannot 
be excluded. The positive effect of oral folic acid after three 
years of follow-up on 3 cognitive domains in participants 
with high homocysteine and low vitamin B12 status which 
was found by Durga et al is also promising, but has not been 
replicated by others. For statin treatment and type II DM 
management, no preventive effects on cognitive decline or 
dementia were found. In many trials, participants were rela-
tively young and, consequently, the incidence of dementia 
was low. Several forms of bias can be identified in the studies 
included in this review, which will be discussed below.
Selective dropout of participants due to cognitive impair-
ment is a serious concern in the reviewed trials, especially 
if a study is not designed to explicitly monitor cognitive 
function. Cognitive impairment may lead to withdrawal of 
informed consent or to institutionalization. Such selective 
dropout could dilute a potential treatment effect and thus 
contribute to a type II error, especially if this form of dropout 
occurs more often in the control group, in case of an effective 
intervention. In a few trials this potential limitation has been 
acknowledged, leading to uncertainty about the validity of 
the results.
In all studies on hypertension, additional treatment with 
other antihypertensive medication was allowed in both the 
intervention group and the placebo group if necessary to 
achieve acceptable blood pressure values. Consequently, 
many patients in the control groups received antihypertensive 
medication, potentially decreasing the experimental contrast 
and thus the effect on both the cardiovascular endpoints and 
cognitive decline. In the cholesterol studies this additional 
treatment with statins other than the study drug occurred less 
frequently, because these studies were done before statins 
were widely prescribed as secondary prevention. In the 
homocysteine lowering trials, additional open label treatment 
was not a major concern.
The population under study in most trials is relatively 
young to find an effect on cognitive decline and certainly on 
incident dementia within the follow-up time. In the age-range 
65–69, dementia is still relatively rare with an incidence of 
approximately 2.4 per 1000, which rises sharply with age 
to a rate of 70.2 per 1000 at age 90 and over.1 As a conse-
quence, the number of participants with incident dementia 
or significant cognitive decline was expected to be low in 
most studies, limiting the power of studies to find such an 
effect. Except for some of the homocysteine lowering tri-
als, most trials were not powered to measure an effect on 
cognitive decline.
Treating cardiovascular risk factors has a clear effect on 
mortality, which should be considered as a competing risk for 
dementia. Since the incidence of dementia is strongly depen-
dent on age, reducing mortality by preventing cardiovascu-
lar disease could lead to an actual increase of the absolute 
number of dementia cases in the intervention groups due to 
increased life expectancy. None of the included studies with 
a treatment effect on mortality addressed competing risks.54 
Taking these considerations into account, the conclusions 
about cognitive decline and dementia should be interpreted 
with caution. Table 4 summarizes the main limitations and 
sources of bias which should be considered when interpreting 
the results of the studies discussed.
This review is limited to studies on medical treatment 
of five common cardiovascular risk factors. We aimed at 
including all randomized trials of sufficient quality assess-
ing cognitive decline or dementia as primary or secondary 
outcome parameter. The association between cardiovascular 
risk factors and cognitive decline and dementia started to 
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studies like the Rotterdam study became available in 1997.55 
Therefore we limited the time period of our literature search. 
Studies reporting on the relationship between antihyperten-
sive drugs and cognition that were published before 1995 
concentrated on the difference between two antihypertensive 
drugs to evaluate a negative effect on cognition on short term 
by a certain drug class, rather than looking for cognitive 
decline on the long term.
RCTs investigating lifestyle interventions including 
physical activity and diet were not taken into account for this 
review. To our knowledge, no RCTs on lifestyle interventions 
with a sufficiently long follow-up to assess any long-term 
effect on cognition or incident dementia are available.
As in any field, publication bias may have influenced the 
results of our search. RCTs in which no positive outcome 
on cognition was found might have been missed, when this 
secondary outcome parameter is not referred to in titles or 
abstracts. This is unfortunate, because when cognitive decline 
is adequately analyzed, a negative outcome is of equal inter-
est to the field.
Meta-analyses of separate risk factors were not per-
formed. For hypertension, two meta-analyses are already 
available and no additional studies have been published 
in the meantime.34,36 The trials on homocysteinemia were 
considered too diverse in the populations targeted and the 
outcomes measured to pool their results. Finally, sources of 
bias cannot be controlled for in a meta-analysis, while these 
represented an important objective in this review.
The large amount of data from observational studies on the 
correlation between different cardiovascular risk factors and 
dementia and the inconclusive results of the RCTs discussed 
in this review call for new RCTs with longer follow-up, in 
sufficiently aged populations, while avoiding methodological 
pitfalls specific to this field (Table 4).   Perhaps different popu-
lations should be targeted (eg, participants in different age 
groups and with different vascular risk profiles), and perhaps 
other interventions should be probed (eg, combined interven-
tions or specific drug classes). Calcium channel blockers are 
of special interest because they were the drug under study in 
the only trial in which a clear effect of blood pressure lower-
ing on incident dementia was found. In a recently published 
prospective cohort study, angiotensin receptor blockers are 
shown to be associated with a significant reduction in the 
incidence of (Alzheimer’s) dementia when compared to other 
antihypertensive drugs.56
A serious concern is that placebo-controlled trials are 
often not possible for obvious ethical reasons. Additionally, 
it is difficult to reach a sufficient level of contrast between 
the intervention and control group when targeting vascular 
risk factors in patients at high risk, since treatment of these is 
clearly indicated to prevent cardiovascular disease. Therefore, 
strategies should be designed in which for instance regular 
care is compared to intensive care. An interesting advantage 
of such trials is that they focus on the cardiovascular risk 
profile as a whole instead of one risk factor at a time. In the 
DEBATE study such an intervention showed no clinical ben-
efit, but the groups were small (n = 199/201) and many par-
ticipants were already participating in secondary prevention 
programs due to relatively high risk of cardiovascular disease 
(81% had coronary artery disease). At least three more RCTs 
on cardiovascular risk factors and cognition are ongoing. 
The Accord-mind study is aimed at investigating the effect 
of intensive diabetes control with blood pressure control or 
lipid lowering therapy.51 The preDIVA study investigates 
Table 4 Main limitations in the reviewed studies
Limitation Remarks
1. Age group relatively young to see any effect on dementia within follow-up – Low number of cases: applies to most studies
2.   High number of dropouts, potentially selective dropout due to cognitive decline – Applies to most studies
3.   Placebo group received additional treatment (contamination) –   Present in most studies on antihypertensive 
treatment and to a lesser extent in cholesterol 
lowering trials
4. Bias in outcome measurement (dementia or cognitive decline)  –   All studies on hypertension and dyslipidemia assessed 
dementia or cognitive decline as a secondary 
outcome parameter, criteria not always clear
5. Competing risks not taken into account –   Correction for increased life expectancy was not 
applied
6. Sensitivity of measurement insufficient –   Optimal screening instrument (crude or sensitive) 
and clinical relevance are matter of debate
7. Short follow-up  – Optimal follow-up time is unclear
8. Small groups, insufficient power – Applies to some studies on lowering homocysteine
9.   Patient group not selected on risk factor (no clear hypertension,  
dyslipidemia, hyperhomocysteinemia)
–   Insufficient window of opportunity to see any effect 
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whether a nurse-led intervention aiming at improvement 
of the cardiovascular risk profile with an individualized 
approach including both lifestyle interventions and medical 
interventions can prevent dementia in an elderly population 
(70–78 years) with a 6-year follow-up.57 The Finger-study 
is designed to delay cognitive impairment in subjects at 
high risk of dementia through a multidomain individualized 
intervention.58
Based on the studies reviewed here we conclude that 
there is insufficient evidence that medical treatment 
aimed at cardiovascular risk factors can prevent cognitive 
decline or dementia. Whereas antihypertensive treatment 
potentially has a preventive effect, this is less clear for 
treatment with statins and intensified type II diabetes mel-
litus management. Results on therapy aimed at lowering 
homocysteine levels are ambiguous and more long-term 
follow-up trials are needed. It may well be that differential 
dropout, lack of power, competing risks, or other forms of 
selection or treatment bias have diluted possible effects. 
Future RCTs in other populations with different interven-
tions and longer follow-up, specifically designed to detect 
an effect on cognitive decline or dementia, will hopefully 
address the central question whether the associations found 
in cohort studies can be translated to clinically relevant 
treatment effects on cognition.
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